title: [Ticlopidine-induced neutropenia].
abstract: Ticlopidine (TCP) is a drug that inhibits platelet aggregation. Several studies have demonstrated its superiority over aspirin in preventing stroke and other thromboembolic diseases. However, neutropenia occurs in about 2% of TCP-treated patients, which therefore may advance to agranulocytosis, sepsis and death. They should be carefully followed with blood counts. We report 2 patients hospitalized with severe neutropenia while on TCP, despite having had regular blood counts. Their complications underline the need for patient selection and meticulous follow-up when ticlopidine is prescribed.
authors.affiliation: Dept. of Medicine B, Bnai Zion Medicial Center, Technion Faculty of Medicine, Haifa.
authors.forename: A
authors.initials: A
authors.lastname: Balbir
authors.forename: M
authors.initials: M
authors.lastname: Odeh
authors.forename: D
authors.initials: D
authors.lastname: Atias
authors.forename: A
authors.initials: A
authors.lastname: Oliven
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology; D013988:Ticlopidine / Q000009:adverse effects*
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine